trial

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

NCTId NCT01300364
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Unknown
Enrollment 249 (estimated)
Sponsored by Fundació Sant Joan de Déu
Primary completion 2011-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Unknown
Enrollment
249 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-11
Primary completion
2011-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Reboxetinecitalopram (SSRI)

Sponsors

Fundació Sant Joan de DéuLead Sponsor
Centro de Investigación Biomédica en Red de Salud MentalCollaborator

Sites

1 total
Sant Boi Llobregat, Spain

Facts & assertions

4 sourced
Enrollment
249
Phase
PHASE4
Primary Completion Date
2011-12
Status
UNKNOWN
relationships
The graph out of here
drug
Reboxetine
drug
citalopram (SSRI)
drug
lead_sponsor
Fundació Sant Joan de Déu
company
collaborator
Centro de Investigación Biomédica en Red de Salud Mental
company
indication
Schizophrenia
indication
Schizophrenia
indication